All individual tested biomarkers (AFP, AFP-L3, and DCP) and scoring models were significantly elevated among early-stage and any-stage HCC patients in comparison to CLD patients (all p-values <0.001) (Figure 1). This evidence concerns the gene AFP and hepatocellular carcinoma.